SCHEMBL6800890

SCHEMBL6800890

CCc1ccc(-c2ccccc2C(=O)Nc2ccc(NCCc3csc(C)n3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 11/20 0.51
RAB9A P51151 11/20 0.51
STAT1 P42224 2/20 0.51
KDM4E B2RXH2 2/20 0.51
SMN1; SMN2 Q16637 6/20 0.49
MAPT P10636 4/20 0.49
TP53 P04637 3/20 0.47
LMNA P02545 1/20 0.47
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 2/20 0.45
RELA Q04206 2/20 0.45
NAMPT P43490 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
PAX8 Q06710 1/20 0.42
KLF5 Q13887 1/20 0.42
MAPK1 P28482 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795866 0.91 NPC1 (0.53) NPC1RAB9ASTAT1KDM4ESMN1; SMN2
SCHEMBL6905219 0.90 TP53 (0.46) NPC1RAB9ASTAT1KDM4ESMN1; SMN2
SCHEMBL6789318 0.90 NPC1 (0.52) NPC1RAB9ASTAT1KDM4ESMN1; SMN2
SCHEMBL6794470 0.88 TP53 (0.54) NPC1RAB9ASTAT1KDM4ESMN1; SMN2
SCHEMBL6794654 0.88 GAA (0.57) NPC1RAB9ASTAT1KDM4ESMN1; SMN2
SCHEMBL6794768 0.84 RAB9A (0.45) NPC1RAB9AKDM4ESMN1; SMN2MAPT
SCHEMBL6792277 0.83 NPC1 (0.46) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL6788552 0.82 RAB9A (0.51) NPC1RAB9AKDM4ESMN1; SMN2MAPT
SCHEMBL6793046 0.82 NPC1 (0.47) NPC1RAB9ASTAT1KDM4ESMN1; SMN2
SCHEMBL6502168 0.82 NPC1 (0.51) NPC1RAB9ASTAT1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 NPC1 64/4885RAB9A 3707/4885STAT1 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.